CN103906520A - 用于治疗行为和精神病症的鲨肌醇 - Google Patents

用于治疗行为和精神病症的鲨肌醇 Download PDF

Info

Publication number
CN103906520A
CN103906520A CN201280037339.8A CN201280037339A CN103906520A CN 103906520 A CN103906520 A CN 103906520A CN 201280037339 A CN201280037339 A CN 201280037339A CN 103906520 A CN103906520 A CN 103906520A
Authority
CN
China
Prior art keywords
inositol
scyllo
dementia
patient
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280037339.8A
Other languages
English (en)
Chinese (zh)
Inventor
S·阿布沙克拉
G·克兰斯
J·塞达尔鲍姆
R·埃尔南德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Publication of CN103906520A publication Critical patent/CN103906520A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280037339.8A 2011-06-03 2012-06-04 用于治疗行为和精神病症的鲨肌醇 Pending CN103906520A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161520031P 2011-06-03 2011-06-03
US61/520,031 2011-06-03
US201161541333P 2011-09-30 2011-09-30
US61/541,333 2011-09-30
US201261618680P 2012-03-31 2012-03-31
US61/618,680 2012-03-31
PCT/US2012/040789 WO2012173808A1 (en) 2011-06-03 2012-06-04 Scyllo-inositol for the treatment of behavioral and psychiatric disorders

Publications (1)

Publication Number Publication Date
CN103906520A true CN103906520A (zh) 2014-07-02

Family

ID=46298680

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280037339.8A Pending CN103906520A (zh) 2011-06-03 2012-06-04 用于治疗行为和精神病症的鲨肌醇

Country Status (11)

Country Link
US (1) US20140243422A1 (https=)
EP (1) EP2714050A1 (https=)
JP (1) JP2014515408A (https=)
KR (1) KR20140041670A (https=)
CN (1) CN103906520A (https=)
AU (1) AU2012271068A1 (https=)
BR (1) BR112013031117A8 (https=)
CA (1) CA2837926A1 (https=)
IL (1) IL229658A0 (https=)
RU (1) RU2013154699A (https=)
WO (1) WO2012173808A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901282A (zh) * 2019-12-02 2022-08-12 苏文生命科学有限公司 在痴呆患者中治疗行为和精神症状

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2014110234A1 (en) * 2013-01-09 2014-07-17 Elan Pharmaceuticals, Llc Methods of treating developmental and personality disorders
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170000809A1 (en) * 2015-06-30 2017-01-05 Jds Therapeutics, Llc Arginine silicate inositol for improving cognitive function
WO2017029353A1 (en) * 2015-08-20 2017-02-23 Transition Therapeutics Ireland Limited Treatment of behaviors in dementia patients
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
CN109890384A (zh) 2016-09-01 2019-06-14 Jds治疗有限公司 生物素镁组合物和使用方法
MX2021005213A (es) 2018-11-02 2021-09-08 Nutrition 21 Llc Composiciones que contienen complejos de silicato de arginina estabilizado con inositol y inositol para mejorar funciones cognitivas en jugadores de videojuegos.
HRP20250882T1 (hr) * 2019-12-02 2025-09-26 Suven Life Sciences Limited Kombinacije masupirdina sa donepezilom ili memantinom za liječenje bihevioralnih i psiholoških simptoma kod pacijenata sa demencijom
IL294021A (en) 2019-12-16 2022-08-01 Nutrition 21 Llc Methods of production of arginine-silicate complexes
JP2025530190A (ja) * 2022-09-07 2025-09-11 エアジェン ファーマ リミテッド アルツハイマー病治療のための免疫療法薬とｓｃｙｌｌｏ－イノシトールとの組み合わせ
CN115998724B (zh) * 2023-03-28 2023-06-16 中国人民解放军军事科学院军事医学研究院 布洛芬在抗幻觉作用药物中的新用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075882A1 (en) * 2003-02-27 2004-09-10 Ellipsis Biotherapeutics Corporation Methods of preventing, treating and diagnosing disorders of protein aggregation
CN101505741A (zh) * 2006-03-09 2009-08-12 瓦拉塔药品公司 用于治疗蛋白积聚病症的环己烷多元醇制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156203A0 (en) * 2003-05-29 2003-12-23 Yissum Res Dev Co Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
ATE458042T1 (de) 2003-10-14 2010-03-15 Hokko Chem Ind Co Verfahren zur herstellung von scyllo-inositol
EP1996175A4 (en) * 2006-03-09 2009-06-10 Waratah Pharmaceuticals Inc CYCLOHEXAN POLYALKOHOL FORMULATION FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
AU2011215616A1 (en) 2010-02-15 2012-09-06 Transition Therapeutics Ireland Limited Process for the preparation of scyllo-Inositol
US20150306043A1 (en) * 2012-09-28 2015-10-29 Transition Therapeutics Ireland Limited Combination treatments for bipolar disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075882A1 (en) * 2003-02-27 2004-09-10 Ellipsis Biotherapeutics Corporation Methods of preventing, treating and diagnosing disorders of protein aggregation
CN101505741A (zh) * 2006-03-09 2009-08-12 瓦拉塔药品公司 用于治疗蛋白积聚病症的环己烷多元醇制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DANIELA FENILI 等: "Properties of scyllo–inositol as a therapeutic treatment of AD-like pathology", 《JOURNAL OF MOLECULAR MEDICINE》 *
JOANNE MCLAURIN 等: "Cyclohexanehexol inhibitors of Ab aggregation prevent and reverse Alzheimer phenotype in a mouse model", 《NATURE MEDICINE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901282A (zh) * 2019-12-02 2022-08-12 苏文生命科学有限公司 在痴呆患者中治疗行为和精神症状

Also Published As

Publication number Publication date
BR112013031117A8 (pt) 2018-08-14
WO2012173808A1 (en) 2012-12-20
KR20140041670A (ko) 2014-04-04
IL229658A0 (en) 2014-01-30
RU2013154699A (ru) 2015-07-20
BR112013031117A2 (pt) 2018-06-19
AU2012271068A1 (en) 2013-12-19
EP2714050A1 (en) 2014-04-09
CA2837926A1 (en) 2012-12-20
JP2014515408A (ja) 2014-06-30
US20140243422A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
CN103906520A (zh) 用于治疗行为和精神病症的鲨肌醇
Mayer et al. Insomnia in central neurologic diseases–occurrence and management
P Cardinali et al. Clinical aspects of melatonin intervention in Alzheimer's disease progression
Yanai et al. Safety considerations in the management of allergic diseases: focus on antihistamines
Winslow et al. Treatment of Alzheimer disease
AU2024227357A1 (en) Ganaxolone For Use In Treating Genetic Epileptic Disorders
US11033543B2 (en) Methods of providing weight loss therapy in patients with major depression
US12594255B2 (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
JP2024050575A (ja) Ｌ－４－クロロキヌレニンの治療的使用
Dalvi Alzheimer's disease
WO2018150276A2 (en) The combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological conditions
Savić et al. Two cases of loss of consciousness after long-term memantine treatment
Scuteri et al. Requirements for translation in clinical trials of aromatherapy: the case of the essential oil of bergamot (BEO) for management of agitation in severe dementia
CN118338899A (zh) 增加人类恢复性睡眠的大麻二酚(cbd)和萜烯制剂
CA3026152C (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
Sarkar et al. Role of Nutraceuticals in the Prevention and Management of Degenerative Diseases
EP3478279A1 (en) Combinations of beta-glycolipides and 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol, compositions and uses thereof in the treatment of disorders associated with protein misfolding and protein aggregations
Lazowski An Investigation of Sleep Architecture and Consequent Cognitive Changes in Olanzapine Treated Patients with Depression
WO2023215338A1 (en) Compositions and methods for treating cluster headache
WO2023215344A2 (en) Compositions and methods for treating cluster-tic syndrome
WO2023215342A1 (en) Compositions and methods for treating trigeminal neuralgia
HK40114348A (zh) 增加人类恢复性睡眠的大麻二酚(cbd)和萜烯制剂
Vgenopoulou et al. Melatonin levels in Alzheimer disease
CN118613265A (zh) 用于治疗神经变性疾病的胆汁酸和苯基丁酸化合物的组合
Farooqui Effects of Long Term Consumption of High Calorie Diet on Neurological Disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140702

WD01 Invention patent application deemed withdrawn after publication